Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) signs IP transfer agreement on molecule that can be potential drug candidate for dementia
Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) signed two agreements with business establishments for transfer of two technologies from its research initiatives, on the eve of ‘Technology Day 2022’, on May 10. JNCASR is an autonomous institute in Bengaluru under the Department of Science and Technology of the Central Government.
One IP transfer agreement pertains to a molecule that could be a potential drug candidate for dementia. The other is for a robust, mobile group oxygen concentrator that can be used in remote settings and deployed in emergencies.
T Govindaraju, a scientist at the JNCASR, and his team have developed the molecule that could be a potential drug candidate to halt or cure the leading cause of dementia in 70 to 80% cases worldwide. This research work was patented and published in the journal Advanced Therapeutics and patented by the JNCASR. The research aimed to design and synthesise molecules that can reduce the toxicity of amyloid peptide — that accumulates in the central nervous system, it said.
th